There are currently no licensed vaccines or therapeutics for COVID‐19. Anti‐SARS CoV‐2
antibody‐containing plasmas, obtained from the recovered individuals who had confirmed …

Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life
of several hundred thousand worldwide. However, so far no approved vaccine or drug …

Introduction COVID‐19, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐
CoV‐2), is a public health crisis. Prior studies demonstrated successful use of convalescent …

The purpose of this systematic review and meta‐analysis was to examine clinical outcomes
associated with convalescent plasma therapy in COVID‐19 patients. We performed a …

Introduction Passive antibody therapy has been used to immunize vulnerable people
against infectious agents. In this study, we aim to investigate the efficacy of convalescent …

Abstract Introduction South America is one of the regions most affected by the COVID‐19
pandemic. Specific and affordable treatments are needed to treat SARS‐CoV‐2 infection …

Background Convalescent plasma (CP) has been widely used to treat COVID-19 and is
under study. However, the variability in the current clinical trials has averted its wide use in …

The objective of this study was to highlight the global scientific effort to fight the SARS-CoV-
2, addressing the preliminary results of passive immunization through convalescent plasma …

Background: The rapidly evolving coronavirus disease 2019 (COVID-19) has resulted in
more than 24 million infections and 821 thousand deaths. However, a vaccine or specific …

Aim Convalescent plasma proved to increase survival rates in other severe viral infections.
Therefore, convalescent plasma could be a promising treatment option for severe COVID-19 …